This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Yttrium Y-90
- DrugBank Accession Number
- DB13076
- Background
Yttrium 90 has been investigated for the treatment of Colon Cancer and Colorectal Cancer.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Yttrium Y-90 (DB13076)
- Weight
- Average: 89.9072
Monoisotopic: 89.907151443 - Chemical Formula
- Y
- Synonyms
- Yttrium (90 Y)
- Yttrium (90Y)
- Yttrium Y 90
- Yttrium-90
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Yttrium-90 chloride TN98A27Q17 39271-65-3 PCMOZDDGXKIOLL-SGNQUONSSA-K Yttrium-90 citrate J8L3BWC4BD 67023-60-3 YCWCJWQILLXGBP-IEOVAKBOSA-K - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ytracis 1.850 GBq/ml Cis Bio International 2016-09-08 2022-01-19 EU 
Yttriga 150.05 GBq/mL Eckert Ziegler Radiopharma Gmb H 2020-12-16 Not applicable EU Yttriga 150.05 GBq/mL Eckert Ziegler Radiopharma Gmb H 2016-09-08 Not applicable EU
Categories
- ATC Codes
- V10AA01 — Yttrium (90y) citrate colloid
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as homogeneous transition metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a transition metal atom.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous metal compounds
- Class
- Homogeneous transition metal compounds
- Sub Class
- Not Available
- Direct Parent
- Homogeneous transition metal compounds
- Alternative Parents
- Not Available
- Substituents
- Homogeneous transition metal
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 1K8M7UR6O1
- CAS number
- 10098-91-6
- InChI Key
- VWQVUPCCIRVNHF-OUBTZVSYSA-N
- InChI
- InChI=1S/Y/i1+1
- IUPAC Name
- (90Y)yttrium
- SMILES
- [90Y]
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Articular inflammation 1 3 Recruiting Treatment Inoperable Hepatocellular Carcinoma 1 2 Completed Treatment Cholangiocarcinoma 1 2 Completed Treatment Lymphoma 1 2 Recruiting Treatment Hepatocellular Carcinoma 1 2 Recruiting Treatment Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma 1 2 Terminated Treatment Hepatocellular Carcinoma 1 2 Withdrawn Treatment Colon Cancer / Colorectal Cancer 1 1 Active Not Recruiting Treatment Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma / Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma / Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma 1 1 Active Not Recruiting Treatment Recurrent Adult Hodgkin's Lymphoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, suspension Intra-articular Solution Intravenous 1.85 GBq Solution Other 1850 MBq - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 0 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 0 m3·mol-1 Chemaxon Polarizability 1.78 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 21, 2016 02:45 / Updated at March 04, 2021 09:26